At WWDC, Apple confirmed that Siri's cloud layer now runs on a custom Google Gemini model with 1.2 trillion parameters, licensed for roughly $1 billion a year.
Strategically, this is a reversal. The company that built its brand on privacy and vertical integration has handed the core of its AI stack to a direct competitor. The same capabilities Apple announced at WWDC 2024 and never shipped — personal context, on-screen awareness, cross-app actions — now depend on Google Cloud.
→ $250M settlement in May for marketing Siri features that didn't exist
→ debuted at WWDC 2024, delayed March 2025, ads pulled
→ Tim Cook's final keynote before stepping down September 1
→ Siri's cloud inference now runs on Google's infrastructure
Apple didn't close the AI gap. It leased it.
Pragmatic move or structural capitulation in the AI race?
{"comments": [{"index": 1, "role": "Opportunist", "expression_type": "observation", "length": "short", "content": "NVAX headline safety boost; watching for a quick pop."}, {"index": 2, "role": "Momentum", "expression_type": "opinion", "length": "short", "content": "Trend still up; NVAX could ride this narrative."}, {"index": 3, "role": "Trader", "expression_type": "opinion", "length": "short", "content": "Scalping NVAX on this safety headline; tight stops."}, {"index": 4, "role": "Skeptic", "expression_type": "observation", "length": "medium", "content": "Feels like PR spin; real-world data lags, and immunity wanes. NVAX still trails BNT and MOD on volume and coverage."}, {"index": 5, "role": "Questioner", "expression_type": "opinion", "length": "short", "content": "Seems like marketing, not science. I'm staying cautious."}, {"index": 6, "role": "Sector-focused", "expression_type": "opinion", "length": "medium", "content": "For vaccine names, this helps NVAX's positioning, but doesn't fix pricing power. BNT and MOD still dominate distribution and payer contracts."}, {"index": 7, "role": "Sentiment", "expression_type": "skepticism", "length": "long", "content": "I'm not convinced. "NVAX" sounds great, but headlines don't equal outcomes. I've seen this playbook before—clean PR, then months of real-world tracking. Until we see consistent data, I'm staying on the sidelines."}, {"index": 8, "role": "Macro", "expression_type": "opinion", "length": "long", "content": "From a macro lens, this could help NVAX's case if demand stays steady and pricing holds. But with rates higher and fiscal support fading, payer budgets tighten. If reimbursement stays soft, even a safety headline won't offset margin pressure."}]}
